Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR – Get Free Report) was up 13.4% during trading on Monday . The stock traded as high as $12.40 and last traded at $12.40. Approximately 229,908 shares traded hands during trading, an increase of 115% from the average daily volume of 106,765 shares. The stock had previously closed at $10.93.
Wall Street Analyst Weigh In
Separately, Wall Street Zen lowered shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.
Read Our Latest Analysis on ZSQR
Coeptis Therapeutics Price Performance
Coeptis Therapeutics (NASDAQ:ZSQR – Get Free Report) last issued its earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $0.11 million for the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%.
Institutional Trading of Coeptis Therapeutics
Large investors have recently made changes to their positions in the stock. State Street Corp boosted its stake in shares of Coeptis Therapeutics by 35.0% during the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after purchasing an additional 6,962 shares during the period. Steward Partners Investment Advisory LLC boosted its stake in shares of Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after purchasing an additional 2,500 shares during the period. Geode Capital Management LLC boosted its stake in shares of Coeptis Therapeutics by 12.6% during the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after purchasing an additional 4,721 shares during the period. Marshall Wace LLP purchased a new stake in shares of Coeptis Therapeutics during the fourth quarter valued at $259,000. Finally, Yorkville Advisors Global LP purchased a new stake in shares of Coeptis Therapeutics during the third quarter valued at $140,000. 13.88% of the stock is owned by hedge funds and other institutional investors.
Coeptis Therapeutics Company Profile
Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.
Featured Stories
- Five stocks we like better than Coeptis Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
